Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure (LeoDOR)
Repetitive levosimendan infusions for patients with advanced chronic heart failure (LeoDOR) A randomised, double-blind, placebo-controlled multicentre study with parallel group design.
Mortality and rehospitalisation rates are high in the vulnerable phase following heart failure hospitalisation. Previous studies suggest that these events can be reduced by repeat infusions of levosimendan in patients with advanced heart failure.
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 264 participants
Allocation : Randomized
Intervention Model : Parallel Assignment
Masking : Triple (Participant, Care Provider, Investigator)
Primary Purpose : Treatment
Official Title : Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure
Actual Study Start Date : March 8, 2018
Estimated Primary Completion Date : April 1, 2019
Estimated Study Completion Date : December 31, 2019
- Experimental : Levosimendan Arm
- Placebo Comparator : Placebo Arm
Related journal :
- Repetitive levosimendan treatment in the management of advanced heart failure.
|Date last updated at source||2018-08-22|
|Study start date||2018-03-08|
|Estimated primary completion date||2019-04-01|